Brian Shea

Biography

Brian Shea currently serves as Vice President, Legal at uniQure N.V. (Nasdaq: QURE), aNetherlands-based biotechnology company focused on developing novel gene therapies to treat patients with rare diseases, including Huntington's disease, amyotrophic lateral sclerosis (ALS), temporal lobe epilepsy and Fabry's disease. uniQure's drug HEMGENIX® is the world's first approved gene therapy for the treatment of hemophilia B. At uniQure Mr. Shea is responsible for the company's corporate-legal function, including public company compliance and corporate governance, supporting the company's business development, alliance management, finance, IT and investor relations departments. Prior to uniQure, Mr. Shea served as General Counsel at Oncorus, Inc. (Nasdaq: ONCR), a Boston-based biopharmaceutical company developing next-generation, RNA-based immunotherapies to treat various forms of cancer. At Oncorus he oversaw the company's legal and compliance function with particular expertise in public company reporting obligations, stock exchange compliance, strategic transactions and governance matters relevant to the life sciences industry.

He assumed the role of President and Interim Chief Executive Officer at Oncorus to manage the orderly wind down and dissolution of the company.Prior to his in-house roles, Mr. Shea practiced in the strategic transactions group at Ropes & Gray, representing late-stage private and public companies and investment banks in going-public transactions, strategic financings and securities law compliance, primarily in the biotechnology industry. Prior to that, Brian was a corporate associate at Mintz Levin. Brian holds a B.A. from Dartmouth College and a J.D. cum laude from William & Mary Law School, and currently serves on the William & Mary Law School Alumni Association Board of Directors.